🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

24 recruiting trials

for Advanced Glioblastoma

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648Phase 13 sites📍 Los Angeles📍 Denver📍 Nashville RasCal Therapeutics, Inc. · Tests: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases NCT05911230NA1 site📍 Basel University Hospital, Basel, Switzerland · Tests: Advanced diffusion-weighted MRI (ADW-MRI) Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors NCT05283330Phase 18 sites📍 Chicago📍 Iowa City📍 Lexington Orano Med Theranostics, SAS · Tests: ²¹²Pb-DOTAM-GRPR1 Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases NCT05909618Phase 21 site📍 Ramat Gan Sheba Medical Center · Tests: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO], Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO] Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors NCT07523529Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening NCT06512311NA1 site📍 Vienna Medical University of Vienna · Tests: CBMed Drug Screening Plattform The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer NCT07636200NA2 sites📍 Aurora📍 Boulder University of Colorado, Boulder · Tests: Written Exposure-Based Coping Intervention (EASE), Usual Care Control Condition APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors NCT03175224Phase 235 sites📍 Los Angeles📍 Tampa📍 Boston Apollomics Inc. · Tests: APL-101 Oral Capsules Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread NCT07193654Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Intrathecal injection of thiotepa, Stupp regimen (oral temozolomide), Radical radiotherapy, Maximal surgical resection Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma NCT06613841EARLY Phase 12 sites📍 Philadelphia📍 Philadelphia Abramson Cancer Center at Penn Medicine · Tests: Fluciclovine F18 Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors NCT06902350Phase 12 sites📍 Beijing📍 Changchun Chipscreen Biosciences, Ltd. · Tests: CS231295 Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients NCT07461948Phase 31 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biospecimen Collection, Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Diffusion-Relaxation Correlat… A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors NCT05941507Phase 1, Phase 28 sites📍 Los Angeles📍 Boston📍 Ann Arbor LigaChem Biosciences, Inc. · Tests: LCB84, Anti-PD-1 monoclonal antibody SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774n/a68 sites📍 Birmingham📍 Mobile📍 Scottsdale Massive Bio, Inc. · Tests: Clinical Trial Matching A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma. NCT07779798Phase 14 sites📍 Duarte📍 Tampa📍 Houston Crossbow Therapeutics, Inc. · Tests: CBX-663 Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques NCT06623565NA1 site📍 Amsterdam Amsterdam UMC, location VUmc · Tests: Multimodal image-guided resection A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations NCT04094610Phase 1, Phase 268 sites📍 Los Angeles📍 Los Angeles📍 Aurora Turning Point Therapeutics, Inc. · Tests: Oral repotrectinib (TPX-0005) At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860Phase 22 sites📍 Jacksonville📍 Grand Forks Mayo Clinic · Tests: Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment, Questionnaire Administration PH Sensitive MRI Based Resections of Glioblastoma NCT06176066Phase 11 site📍 Los Angeles University of California, Los Angeles · Tests: CEST PH MRI based resection of glioblastoma Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN NCT07627334NA1 site📍 Vienna Medical University of Vienna · Tests: CBmed drug screening platform Anti-GD2 ADC M3554 in Advanced Solid Tumors NCT06641908Phase 111 sites📍 Boston📍 New York📍 Houston EMD Serono Research & Development Institute, Inc. · Tests: M3554 Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas NCT06640582Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine, Interleukin-2, Pembrolizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy